Volume 6.26 | Jul 10

Cord Blood News 6.26 July 10, 2014
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
Retention of Stemness and Vasculogenic Potential of Human Umbilical Cord Blood Stem Cells after Repeated Expansions on PES-Nanofiber Matrices
Previously, the authors reported a PES-nanofiber based ex vivo stem cell expansion technology, which supports expansion of human umbilical cord blood-derived CD133+/CD34+ progenitor cells ~225 fold. They show that using similar technology and subsequent re-expansion methods, they can achieve ~5 million-fold yields within 24 days of the initial seeding. [Biomaterials] Abstract
Technical Bulletin: Assays For Cord Blood
PUBLICATIONS (Ranked by impact factor of the journal)
Early Administration of Donor Lymphocyte Infusions upon Molecular Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia: A Study by the Chronic Malignancies Working Party of the EBMT
Investigators analyzed 155 patients who relapsed after allogeneic stem cell transplantation for chronic myeloid leukemia with disease detectable only by molecular methods and who subsequently received lymphocytes. [Haematologica] Abstract | Full Article

Molecular and Functional Analyses of Motor Neurons Generated from Human Cord Blood Derived Induced Pluripotent Stem Cells
Scientists present for the first time the differentiation of human cord blood derived induced pluripotent stem cells into motor neurons, the cell type primarily affected in amyotrophic lateral sclerosis. [Stem Cells Dev] Abstract

Umbilical Cord Mesenchymal Stem Cells Suppress Host Rejection: The Role of the Glycocalyx
Investigators aimed to determine the key components involved in the ability of the umbilical cord mesenchymal stem cells (UMSCs) to modulate the inflammatory system, and to identify the inflammatory cells that are regulated by the UMSCs. [J Biol Chem] Abstract | Full Article

Donor-Recipient Allele-Level HLA Matching of Unrelated Cord Blood Units Reveals High Degrees of Mismatch and Alters Graft Selection
Investigators analyzed the high-resolution donor-recipient HLA match of 100 double-unit 4-6/6 HLA-A,-B antigen, -DRB1 allele-matched cord blood grafts and their back-up units. [Bone Marrow Transplant] Abstract

Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Using Fludarabine-, Intravenous Busulfan- and Low-Dose TBI-Based Conditioning
Researchers report their institutional experience with 27 myelofibrosis patients who underwent hematopoietic cell transplantation using fludarabine-, intravenous BU- and low-dose total body irradiation-based reduced-intensity or full-intensity conditioning regimens. [Bone Marrow Transplant] Abstract

Impact of Recipient ABH Secretor Status on Outcome in Minor ABO-Incompatible Hematopoietic Stem Cell Transplantation
As ABH substances are expressed on tissues and secreted in body fluids, they could drive an immune response in minor ABO-incompatible hematopoietic stem cell transplantation. Researchers aimed to investigate the prognostic role of the recipients’ ABH secretor status. [Transfusion] Abstract

Non-Traditional CD4+CD25CD69+ Regulatory T Cells Are Correlated to Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Non-traditional CD4+CD25CD69+ T cells were found to be involved in disease progression in tumor-bearing mouse models and cancer patients recently. Scientists attempted to define whether this subset of T cells was related to leukemia relapse after allogeneic hematopoietic cell transplantation. [J Transl Med] Full Article

Two-Way Regulation between Cells and Aligned Collagen Fibrils: Local 3D Matrix Formation and Accelerated Neural Differentiation of Human Decidua Parietalis Placental Stem Cells
Researchers report on the concerted changes of human decidua parietalis placental stem cells and the highly ordered collagen fibril matrix in response to cell-matrix interaction. [Biochem Biophys Res Commun] Abstract

International Society for Experimental Hematology 43rd Meeting
Umbilical Cord Blood Mesenchymal Stem Cells Co-Modified by TERT and BDNF: A Novel Neuroprotective Therapy for Neonatal Hypoxic-Ischemic Brain Damage
Telomerase reverse transcriptase (TERT)- and brain-derived neurotrophic factor (BDNF)-modified umbilical cord blood mesenchymal stem cells may have a longer lifespan and also maintain neural differentiation, thus promoting the recovery of neurological function following hypoxic-ischemic brain damage (HIBD) and thereby representing a new effective strategy for HIBD in neonates. [Int J Dev Neurosci] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Fraunhofer Life Science Symposium
Pluristem Initiates South Korean Arm of Multinational Phase II Intermittent Claudication Trial
Pluristem Therapeutics Inc. announced the initiation of South Korean sites in the Phase II study assessing placental expanded cells in the treatment of intermittent claudication. [Pluristem Therapeutics Inc.]
Press Release

University of Pennsylvania’s Personalized Cellular Therapy for Leukemia Receives FDA’s Breakthrough Therapy Designation
A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia. The investigational therapy, known as CTL019, is the first personalized cellular therapy for the treatment of cancer to receive this classification. [Penn Medicine] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Advances in Stem Cell Research 2014
September 16-17, 2014

Visit our events page to see a complete list of events in the cord blood community.
NEW Hematology Investigator (Case Western Reserve University)

Postdoctoral Fellow – Intense Immunosuppression Followed by Autologous Hematopoietic Stem Cell Transplantation (University of Genoa)

Grant Writer – Pediatric Hematology, Oncology, Stem Cell Transplant, and Cancer Biology (Stanford University School of Medicine)

Cord Tissue Processing Technician (Cord Blood Registry)

Clinical HSCT Faculty Position (University of Wisconsin School of Medicine and Public Health)

Postdoctoral Position – Hematopoietic Stem Cell Research (UT Southwestern Medical Center at Dallas)

Research Associate – Hematology/Oncology (University of Chicago)

Postdoctoral Researcher – Hematopoietic Stem Cells & iPSCs (KU Leuven)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us